

Table S1. Characteristics of the patients, mean age 54.66 ± 5.08 ; range 23-79 yrs.*Patients with a diagnosis of cancer were free of metastatic disease and peritoneal involvement.

Age	Gender	Diagnosis*	Drugs
21	F	Colonic cancer	No
23	M	Hepatic hydatidosis	No
27	M	Rectal cancer	No
32	F	Rectal cancer	No
39	F	Cholelithiasis	Omeprazol Lorazepam Fluoxetin
42	F	Rectal cancer	No
44	F	Rectal cancer	No
46	M	Colonic cancer	No
51	M	Colonic cancer	No
55	M	Colonic cancer	No

Cell culture

HPMCs were isolated from omental tissue from 10 different donors (free of any cardiovascular or peritoneal disease and non-taking anti-inflammatory drugs or antioxidants) undergoing nonurgent, non-septic abdominal surgery, using previously described methods (Chung-Welch et al., 1997). HPMC were routinely cultured in M199 containing 1 g l⁻¹ of D-glucose and supplemented with 10% FCS, 100 mgml⁻¹ streptomycin, 100Uml⁻¹ penicillin, and 2.5 mgml⁻¹ amphotericin. At confluence, HPMC were passaged using a 0.02% EDTA–0.05% trypsin solution and split in a 1:2 ratio.

HPMCs characterization was based on both cell morphology (immediately prior to and at confluence, cells adopted the polygonal cobblestone-like appearance characteristic of epithelial cells and formed a monolayer) and indirect immunofluorescence staining of several human mesothelial markers (Chung-Welch et al., 1997). In brief, HPMC showed a diffuse positive staining with an anti-von Willebrand factor antibody (Dakopatts, Glostrup, Denmark) and a marked staining with anti-cyokeratins 8 and 18, anti-E-cadherin, and anti-vimentin antibodies (all of them from Sigma Chemical Co.). HPMC failed to express the endothelial marker PECAM-1 (CD31) (see Supplemental data, Table 2).

Table S2. HPMC characterization.

<i>Markers</i>	<i>HPMC</i>	<i>HAEC</i>	<i>HUVEC</i>	<i>HASMC</i>
<i>Factor VIII (vWF)</i>	+/- (diffuse)	+++ (granular)	+++ (granular)	negative
<i>α-actin</i>	negative	negative	negative	+++
<i>E-Cadherin</i>	++	negative	negative	
<i>VE-Cadherin</i>	+++	++	++	
<i>Vimentin</i>	+++	++	++	
<i>Cytokeratin 8</i>	++	++	++	
<i>Cytokeratin 18</i>	++	++	++	
<i>PECAM-1(CD31)</i>	negative	++		

HPMC, Human Peritoneal Mesothelial Cells; **HAEC**, Human Aortic Endothelial Cells; **HUVEC**, Human Umbilical Vascular Endothelial Cells; **HASMC**, Human Aortic Smooth Muscle Cells. The morphologic and immunofluorescence-staining features of the

cells remained stable throughout the passages used.

Preparation of Amadori adducts

Lyophilised human haemoglobins, nonenzymatically glycosylated at either elevated or normal levels, containing 11.1% and 5.4% HbA1, respectively, were purchased from Sigma. Briefly, haemoglobins were dissolved in deionised water and subsequently reduced by incubation with an excess of sodium dithionite. The haemoglobin solutions were then extensively dialysed using a 0.25A° pore diameter (approximately 12 kDa mol wt) dialysis membrane (Viskings, Serva, Heidelberg, Germany) against deionised water containing 10mg^l⁻¹ EDTA and continuously bubbled with N₂. Oxyhaemoglobins were then aliquoted and stored at -70 °C until used.

The absence of AGEs in the glycated oxyhaemoglobin solutions was assessed by measuring fluorescence in a Fluostar fluorometer (BMG Labtechnologies, Offenburg, Germany) at excitation maximum of 370 nm and emission maximum of 440 nm, which allows quantifying total AGEs (Sell & Monnier, 1989). A standard curve ($r^2=0.99$) was carried out using AGE-modified BSA (0.5–5 mgml⁻¹), prepared following a previously described method (Bucala et al., 1991). Glycated preparations did not contain significant bacterial endotoxin contamination (<0.5U endotoxin ml⁻¹), as measured with Pyrogens plus kit (Biowhittaker Europe SPRL, Verviers, Belgium).